Vivjoa

(Oteseconazole - antifungal therapy 1)

Small molecule

MMycovia Pharmaceuticals Inc.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Timeline

Expected Milestones

Q2 2032

PreclinicalRecruiting

HIV

NCT06666322

Clinical

Trials by Indication[1]

HIV1 trial

Platform Trial For Cryptococcal Meningitis

Recruiting·UUniversity of Minnesota·Preclinical·NCT06666322·2,000 enrolled

Regulatory

FDA Approval Timeline[3]

Apr 26, 2022

VIVJOA

NDA NDA215888

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oteseconazole - antifungal therapy 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oteseconazole - antifungal therapy 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA215888). U.S. Food & Drug Administration.
[4]
FDA Orange Book — Patent and exclusivity data for Vivjoa. U.S. Food & Drug Administration.
[5]
SEC EDGAR — Mycovia Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: MMycovia Pharmaceuticals Inc.

Patent Landscape[4]

Patent Cliff

Apr 22, 2031

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8754227Apr 22, 2031

8236962Apr 22, 2031

11247981May 9, 2033

9840492Mar 17, 2036

10414751Mar 17, 2036